SpaceX IPO Could Create ‘The Biggest Short Squeeze’ of All Time on Index Funds. Here’s How That Happens.

Quick Read
-
Alphabet (GOOGL) pulled back 8% in a week as rebalancing anxiety builds ahead of a historic $330 billion combined equity supply wave.
-
Float-adjusted rules rank SpaceX 195th in the S&P 500, near Amgen (AMGN) and Gilead (GILD), not in the top tier that actually moves indexes.
-
SpaceX’s 366-day lock-up on 100% of founder shares creates a deliberately scarce float, potentially forcing index funds to buy at any price upon inclusion.
-
Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Google didn’t make the cut. Grab the names FREE today.
The phrase sounds almost impossible: a short squeeze involving index funds. After all, index funds are designed to be passive, rules-based buyers, not active traders caught on the wrong side of a position. Yet that is exactly the scenario Animal Spirits hosts Michael Batnick and Ben Carlson laid out on Episode 467, “The Biggest Short Squeeze of All-Time,” citing Bloomberg columnist Matt Levine. With SpaceX targeting a June 12, 2026, NASDAQ debut under ticker SPCX at a $1.75 to $1.8 trillion valuation, the mechanics are about to be tested in public.
How SpaceX Could Force Index Funds to Buy at Any Price
Levine’s “maximally cynical approach” works like this. A company could “do an IPO, sell like one share of stock to the most ardent possible Elon Musk fan asset manager at a $2 trillion valuation,” lock up everything else, and wait for index inclusion to do the rest. Once the stock qualifies for a major benchmark, every fund tracking that benchmark has to own it.
Forced buyers meeting a deliberately scarce float produce one outcome: “You have effectively created a short squeeze for the index funds. They have to buy stock at any price, and there isn’t enough stock for them to buy.”
SpaceX’s S-1 makes the float math credible. SpaceX’s filing confirms a 366-day lock-up covering 100% of the Founder’s shares and those of significant investors, underwritten by Goldman Sachs. That is the mechanical basis for a stock that trades thin and rich for over a year.
Why the Short-Squeeze Theory May Be Overstated
Bloomberg Intelligence puts the actual passive demand at nearly $20 billion, roughly a quarter of the $75 billion raise. Under float-adjusted index rules, SpaceX would slot in around the 195th position in the S&P 500, near Amgen and Gilead, rather than near the top.
That comparison offers useful context. Amgen (NASDAQ:AMGN) carries a market cap of nearly $182.5 billion with a trailing P/E of 23. Gilead Sciences (NASDAQ:GILD) has a market cap of roughly $160 billion and a trailing P/E of 17. Neither moves the index much on its own, and a float-adjusted SpaceX entering near that rank would not blow up SPY’s top ten. Carlson’s view, that excluding the top-15 names from cap-weighted indexes “would be bizarre,” reflects how index providers have long handled this.
![$850B Valuation, $25B Revenue [2026] $850B Valuation, $25B Revenue [2026]](https://thewallstreetledger.com/wp-content/uploads/2026/06/openai-ipo-850-billion-valuation-2026.webp-390x220.webp)



